EU sees one in 5,000 cancer risk from tainted China heart drug
LONDON (Reuters) - The European Medicines Agency estimates there could be one extra case of cancer for every 5,000 patients taking a common blood pressure and heart drug manufactured in bulk by a Chinese company that has been found to contain an impurity.
The alarm over valsartan was first raised in July, prompting a global recall of affected pills. The EMA believes the problem likely dates back to changes in manufacturing processes at Zhejiang Huahai Pharmaceutical in 2012.In an update on its investigation issued on Thursday, the European drugs watchdog said its one-in-5,000 risk assessment was based on patients taking the highest valsartan dose every day for seven years.NDMA, or N-nitrosodimethylamine, is classified as a probable human carcinogen. Based on results from laboratory tests, it may cause cancer with long-term use.AUGUST 2, 2018https://www.reuters.com/
We use "cookies* to ensure the functionality of our website, recognise your browser or device, learn more about your interests, and provide you with essential features and services and for additional purposes, including:
Recognising you when you sign-in to use our services. This allows us to provide you with product recommendations, display personalised content, and provide other customised features and services. Keeping track of your specified preferences. You may set your preferences through Your Account.. Keeping track of items stored in your shopping basket and personal cabinet. Conducting research and diagnostics to improve ChemDiv’s content, products, and services. Delivering content, including ads, relevant to your interests on ChemDiv’s site Reporting. This allows us to measure and analyse the performance of our services.
By cookies you give consent to the processing of your personal data, including transfer to third parties. Further information can be found in our privacy policy.
